Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells.

Beloueche-Babari M, Jackson LE, Al-Saffar NM, Eccles SA, Raynaud FI, Workman P, Leach MO, Ronen SM.

Mol Cancer Ther. 2006 Jan;5(1):187-96.

2.
3.

Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition.

Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen SM.

Cancer Res. 2005 Apr 15;65(8):3356-63.

5.

Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.

Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H.

J Hematol Oncol. 2012 Jul 11;5:16. doi: 10.1186/1756-8722-5-16.

6.

Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts.

Esmaeili M, Bathen TF, Engebråten O, Mælandsmo GM, Gribbestad IS, Moestue SA.

Magn Reson Med. 2014 Jun;71(6):1973-81. doi: 10.1002/mrm.24869. Epub 2013 Jul 22.

PMID:
23878023
8.

Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.

Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, Sukumar S, Nelson SJ, Vigneron DB, Kurhanewicz J, James CD, Haas-Kogan DA, Ronen SM.

Cancer Res. 2010 Feb 15;70(4):1296-305. doi: 10.1158/0008-5472.CAN-09-2251. Epub 2010 Feb 9.

11.

Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells.

Su JS, Woods SM, Ronen SM.

NMR Biomed. 2012 Feb;25(2):379-88. doi: 10.1002/nbm.1764. Epub 2011 Aug 23.

12.

Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.

Al-Saffar NM, Troy H, Ramírez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL.

Cancer Res. 2006 Jan 1;66(1):427-34.

13.
14.

The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.

Al-Saffar NM, Jackson LE, Raynaud FI, Clarke PA, Ramírez de Molina A, Lacal JC, Workman P, Leach MO.

Cancer Res. 2010 Jul 1;70(13):5507-17. doi: 10.1158/0008-5472.CAN-09-4476. Epub 2010 Jun 15.

17.

A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy.

Bowers RK, Marder P, Green LJ, Horn CL, Faber AL, Thomas JE.

Mol Cancer Ther. 2007 Sep;6(9):2600-7. Epub 2007 Aug 31.

18.

HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells.

Ward CS, Eriksson P, Izquierdo-Garcia JL, Brandes AH, Ronen SM.

PLoS One. 2013 Apr 23;8(4):e62610. doi: 10.1371/journal.pone.0062610. Print 2013.

20.

The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K(V) currents via a direct mechanism.

El-Kholy W, Macdonald PE, Lin JH, Wang J, Fox JM, Light PE, Wang Q, Tsushima RG, Wheeler MB.

FASEB J. 2003 Apr;17(6):720-2. Epub 2003 Feb 5.

PMID:
12586735

Supplemental Content

Support Center